Team DDC

DNA Damage in Cancer

Often termed as a disease of the genome, cancer is the result of random acquisition of mutations that activate oncogenes and inactivate tumor suppressors. Consequently, cellular processes including cell cycle control, transcription, apoptosis and DNA repair are affected, conferring incremental growth advantages to cells and fomenting tumorigenesis.

›

Team RSC

RNA Splicing in Cancer

Emerging data indicate that alterations in RNA splicing play a critical role in the pathogenesis of several molecular subtypes of cancer. Such alterations can lead to constitutive activity of oncogenes, reduced expression of tumor suppressors, or drug resistance. The team is seeking to identify novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.

›

Team PMI

Pathogen-Mediated Modulation of Innate Immunity

The team is interested in identifying key molecular and cellular mechanisms at the pathogen-host interface which could be exploited as potential targets for the treatment of multiple chronic inflammatory diseases.

›

Team IAA

Rapid Identification of Auto-Antigens in Autoimmune Diseases

The team is seeking new platform technologies or concepts which lead to identification of antigens recognized by T cells involved in autoimmune responses.

›

Team TNA

Tau-Mediated Neurodegeneration in Alzheimer's Disease

Alzheimer's disease is the most common form of dementia worldwide, affecting millions of patients with no therapeutic options available to date. While amyloid plaques have long been recognized as hallmarks of the disease, recent evidence suggests that abnormal post-translational modifications of the Tau protein are strongly involved in disease manifestation and progression.

›

Team BMP

Brain Microcircuits in Psychiatric Diseases

Successful treatment of psychiatric diseases remains a major challenge. We explore the contribution of non-neuronal cells to the dysfunction of brain microcircuits underlying mental disorders to provide new, personalized therapies.

›

Team EAC

Epigenetics and COPD

The EAC research team is exploring the role of epigenetic regulation in development and progression of the chronic obstructive pulmonary disease (COPD).

›

Team NBB

Nanomaterial-Based Biosensors

The NBB team at BioMed X combines state-of-the-art nanomaterials research with biomedical know-how in order to develop a novel electronic sensor platform for the next generation of point-of-care diagnostic devices.

›

Team OBD

Oral Biofilm Disruption

Biofilm systems are ubiquitous throughout nature, but of particular interest to our team are the multispecies-biofilms that colonize the oral cavity and cause dental caries and periodontitis.

›

Interested in future calls for application?

Register now

Become part of a strong academic research network at the Heidelberg Campus and acquire new research skills.

BioMed X is located on Heidelberg’s Life Science Campus. Within walking distance you will find such institutions as Heidelberg University Hospital, the German Cancer Research Center, the National Center for Tumor Diseases, the Center for Molecular Biology, BioQuant, and – not far from the campus – the European Molecular Biology Laboratory.

Campus Life